References
- Summa V, Petrocchi A, Bonelli F et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV–AIDS infection. J. Med. Chem.51(18), 5843–5855 (2008).
- Fransen S, Gupta S, Danovich R et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol.83(22), 11440–11446 (2009).
- Eggink D, Langedijk JP, Bonvin AM et al. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J. Biol. Chem.284(39), 26941–26950 (2009).
- Palmer S, Wiegand AP, Maldarelli F et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol.41(10), 4531–4536 (2003).
- Palmer S, Maldarelli F, Wiegand A et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl Acad. Sci. USA105(10), 3879–3884 (2008).
- Vrancken R, Haegeman A, Paeshuyse J et al. Proof of concept for the reduction of classical swine fever infection in pigs by a novel viral polymerase inhibitor. J. Gen. Virol.90(Pt 6), 1335–1342 (2009).
- Bodenreider C, Beer D, Keller TH et al. A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Anal. Biochem.395(2), 195–204 (2009).
- Su XC, Ozawa K, Qi R, Vasudevan SG, Lim SP, Otting G. NMR analysis of the dynamic exchange of the NS2B cofactor between open and closed conformations of the West Nile virus NS2B-NS3 protease. PLoS Negl. Trop. Dis.3(12), e561 (2009).
- Hurt AC, Nor’e SS, McCaw JM et al. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J. Virol.84(18), 9427–9438 (2010).